<?xml version="1.0" encoding="UTF-8"?>
<ref id="B17-viruses-11-00826">
 <label>17.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Clark</surname>
    <given-names>M.P.</given-names>
   </name>
   <name>
    <surname>Ledeboer</surname>
    <given-names>M.W.</given-names>
   </name>
   <name>
    <surname>Davies</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Byrn</surname>
    <given-names>R.A.</given-names>
   </name>
   <name>
    <surname>Jones</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Perola</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Tsai</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Jacobs</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Nti-Addae</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Bandarage</surname>
    <given-names>U.K.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2</article-title>
  <source>J. Med. Chem.</source>
  <year>2014</year>
  <volume>57</volume>
  <fpage>6668</fpage>
  <lpage>6678</lpage>
  <pub-id pub-id-type="doi">10.1021/jm5007275</pub-id>
  <pub-id pub-id-type="pmid">25019388</pub-id>
 </element-citation>
</ref>
